Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
7,519.12
(
0.61%
)
US TECH 100
29,331.20
(
0.41%
)
Dow Jones
50,461.68
(
-0.23%
)
Brent Oil
93.06
(
-4.05%
)
Bitcoin
75,756.30
(
-0.12%
)
News Focus
News Focus
Post# of 257644
Next 10
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 843
Posts 123024
Boards Moderated 9
Alias Born 09/05/2002

DewDiligence

Member Level

Re: DewDiligence post# 193693

Wednesday, 03/01/2017 12:06:21 PM

Wednesday, March 01, 2017 12:06:21 PM

Post# of 257644
ABBV/ENTA—FDA expands Technivie* label to include GT4 patients with CP-A cirrhosis:

https://content.govdelivery.com/accounts/USFDA/bulletins/18a3b91

From a commercial standpoint, this label expansion won’t move the needle for ABBV/ENTA since GT4 is a small population in the US (about 6% of all HCV patients) and the GT4 CP-A population is even smaller. Please see #msg-115667263 for related info.

*Technivie is the US brand name for the 2-DAA variant of Viekira Pak that omits Dasabuvir (the non-nuke third agent).

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Trade Smarter with Thousands

Leverage decades of market experience shared openly.

Join Now